Rivaroxaban in Peripheral Artery Disease after Revascularization

Patients with peripheral artery disease who underwent revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) or placebo. All patients received aspirin. The primary outcome of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or cardiovascul...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 382; no. 21; pp. 1994 - 2004
Main Authors Bonaca, Marc P, Bauersachs, Rupert M, Anand, Sonia S, Debus, E. Sebastian, Nehler, Mark R, Patel, Manesh R, Fanelli, Fabrizio, Capell, Warren H, Diao, Lihong, Jaeger, Nicole, Hess, Connie N, Pap, Akos F, Kittelson, John M, Gudz, Ivan, Mátyás, Lajos, Krievins, Dainis K, Diaz, Rafael, Brodmann, Marianne, Muehlhofer, Eva, Haskell, Lloyd P, Berkowitz, Scott D, Hiatt, William R
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 21.05.2020
Subjects
Aged
Amputation
Aspirin
Aspirin - adverse effects
Aspirin - therapeutic use
Bleeding
Cardiovascular disease
Cardiovascular Diseases - epidemiology
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Cerebral infarction
Combined Modality Therapy
Committees
Confidence intervals
Design
Double-Blind Method
Drug Therapy, Combination
Endovascular Procedures
Factor Xa Inhibitors - adverse effects
Factor Xa Inhibitors - therapeutic use
Female
Heart attacks
Hemorrhage - chemically induced
Hemorrhage - epidemiology
Humans
Hypotheses
Incidence
Ischemia
Ischemia - epidemiology
Ischemia - prevention & control
Kaplan-Meier Estimate
Lower Extremity - blood supply
Male
Middle Aged
Myocardial infarction
Peripheral Arterial Disease - drug therapy
Peripheral Arterial Disease - surgery
Platelet Aggregation Inhibitors - adverse effects
Platelet Aggregation Inhibitors - therapeutic use
Rivaroxaban - adverse effects
Rivaroxaban - therapeutic use
Safety
Site selection
Thrombolysis
Thrombosis
Vascular diseases
Online AccessGet full text

Cover

More Information
Summary:Patients with peripheral artery disease who underwent revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) or placebo. All patients received aspirin. The primary outcome of acute limb ischemia, major amputation for vascular causes, MI, ischemic stroke, or cardiovascular death occurred less frequently with rivaroxaban.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2000052